News

The AACR-Bayer HealthCare Basic Cancer Research Fellowships represent a joint effort to provide critical support to postdoctoral and clinical fellows conducting basic cancer research at the earliest stages

The partnership expands Water Street’s pharmaceutical partnership program, which the firm established in 2013 as a new way to support corporations with leveraging their investment in developing pharmaceutical

VT-464 is an oral medication given without prednisone that may represent an improved therapy for men with CRPC and it works by selectively inhibiting CYP17 lyase, a target

MERS is caused by a coronavirus, which is related to the severe acute respiratory syndrome (SARS) virus and currently there is no vaccine or effective treatment for this

The approval was based on data from three Phase III studies, TARGET 1, TARGET 2 and TARGET 3 involving more than 3,000 patients. In these trials, Xifaxan 550mg

Fycompa is indicated to treat PGTC seizures in adult and adolescent patients from 12 years of age with idiopathic generalized epilepsy. Discovered and developed by Eisai, Fycompa is

The drug is indicated for ADPKD patients who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease. Tolvaptan

The company said that Viberzi has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist and a kappa receptor agonist. IBS-D is characterized

Under the deal, the parties plan to pursue development and commercialization of Vibativ in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). The company said that additional indications